Atopic Dermatitis Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Atopic Dermatitis Pipeline Landscape

DelveInsight’s, “Atopic Dermatitis Pipeline Insight, 2022” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.  In the Atopic Dermatitis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Atopic Dermatitis Pipeline Insight Report

• DelveInsight’s analysis presents the Atopic Dermatitis Pipeline with 100+ active players in the domain investigating 100+ pipeline therapies.
• The leading Atopic Dermatitis Companies are working such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
• Promising Atopic Dermatitis Pipeline therapies such as Baricitinib, Lebrikizumab, Benralizumab, MEDI9929, Dupilumab, and others.
• The Atopic Dermatitis Companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Atopic Dermatitis Pipeline Outlook Report

Recent Developmental Activities in the Atopic Dermatitis Pipeline

• Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
• BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
• LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

Atopic Dermatitis Overview

Atopic dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease. Atopic dermatitis is not contagious, so it cannot be spread from person to person. Atopic dermatitis causes the skin to become extremely itchy. Scratching leads to further redness, swelling, cracking, “weeping” clear fluid, crusting, and scaling. In most cases, there are periods of time when the disease is worse, called flares, followed by periods when the skin improves or clears up entirely, called remissions. Researchers do not know what causes atopic dermatitis, but they do know that genes, the immune system, and the environment play a role in the disease. Depending on the severity and location of the symptoms, living with atopic dermatitis can be hard. Treatment can help control symptoms. For many people, atopic dermatitis improves by adulthood, but for some, it can be a lifelong illness.

Atopic Dermatitis Emerging Drugs Profile

• Amlitelimab: Kymab
• BX 005: BiomX
• LP 0145: LEO Pharma

Request for Sample to know more about the Atopic Dermatitis Pipeline Therapeutics Assessment Report @ Atopic Dermatitis Clinical Trials Analysis

Atopic Dermatitis Pipeline Therapeutics Analysis

There are approx. 100+ key companies are developing therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase II include, LEO Pharma.

Atopic Dermatitis Pipeline Therapeutics Assessment

• Atopic Dermatitis Assessment by Product Type
• Atopic Dermatitis By Stage and Product Type
• Atopic Dermatitis Assessment by Route of Administration
• Atopic Dermatitis By Stage and Route of Administration
• Atopic Dermatitis Assessment by Molecule Type
• Atopic Dermatitis by Stage and Molecule Type

Scope of the Atopic Dermatitis Pipeline Report

• Coverage- Global
• Atopic Dermatitis Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
• Atopic Dermatitis Pipeline therapies- Baricitinib, Lebrikizumab, Benralizumab, MEDI9929, Dupilumab, and others
• Atopic Dermatitis Pipeline Therapeutic Assessment

Table of content

1. Introduction
2. Atopic Dermatitis Executive Summary
3. Atopic Dermatitis: Overview
4. Atopic Dermatitis Pipeline Therapeutics
5. Atopic Dermatitis Therapeutic Assessment
6. Atopic Dermatitis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Amlitelimab: Kymab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Atopic Dermatitis Key Companies
21. Atopic Dermatitis Key Products
22. Atopic Dermatitis- Unmet Needs
23. Atopic Dermatitis- Market Drivers and Barriers
24. Atopic Dermatitis- Future Perspectives and Conclusion
25. Atopic Dermatitis Analyst Views
26. Atopic Dermatitis Key Companies
27. Appendix

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Atopic Dermatitis drugs?
• How many Atopic Dermatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atopic Dermatitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atopic Dermatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atopic Dermatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Discover more about the scope of the Atopic Dermatitis pipeline therapies report @ Atopic Dermatitis Treatment Landscape

About Us